|
Acquired platelet disorder
|
0.010 |
Biomarker
|
disease |
BEFREE |
Anti-GPVI-associated ITP: an acquired platelet disorder caused by autoantibody-mediated clearance of the GPVI/FcRgamma-chain complex from the human platelet surface.
|
15150079 |
2004 |
|
Acute Cerebrovascular Accidents
|
0.010 |
Biomarker
|
disease |
BEFREE |
Glycoprotein (GP)Ib-mediated and GPVI-mediated platelet activation, but not GPIIb-IIIa-mediated platelet aggregation, is an important checkpoint that orchestrates thrombotic and pro-inflammatory pathways, and downstream activation of coagulation factor XII is a driving force of ischaemia-reperfusion injury in acute stroke.
|
31263257 |
2019 |
|
Acute Coronary Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
Soluble CLEC-2 is generated independently of ADAM10 and is increased in plasma in acute coronary syndrome: comparison with soluble GPVI.
|
31165998 |
2019 |
|
Acute myocardial infarction
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
In this sample of white non-Hispanic men and women, several SNPs in GP6 were significantly related to risk of AMI.
|
20227257 |
2011 |
|
Acute myocardial infarction
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
There is no association between GP VI T13254C or GP Ia C807T polymorphisms and premature acute myocardial infarction.
|
22627583 |
2012 |
|
Adult Fibrosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
HT1080 fibrosarcoma and C32 melanoma cells utilize GPIV in concert with a heparin-modulated binding systems to attach and spread on TSP.
|
1703153 |
1991 |
|
Amegakaryocytic thrombocytopenia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
To our knowledge, this is the first report that describes a case of amegakaryocytic thrombocytopenia that is not caused by a mutation in MPL and demonstrates the severe impairment of GPVI expression on platelets.
|
18194481 |
2008 |
|
Arteriosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Because CD40L is a potent platelet-derived cytokine that is involved in thrombosis and atherosclerosis, we evaluated the effect of GPVI-mediated release of CD40L on activation of endothelial cells.
|
15277394 |
2004 |
|
Arthritis
|
0.010 |
Biomarker
|
disease |
BEFREE |
This demonstrates that the SNPs tested within the GPVI gene are not associated with RA susceptibility and/or severity, suggesting that platelet GPVI may contribute to arthritis independently of its gene polymorphism.
|
23739280 |
2013 |
|
Atherosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Because CD40L is a potent platelet-derived cytokine that is involved in thrombosis and atherosclerosis, we evaluated the effect of GPVI-mediated release of CD40L on activation of endothelial cells.
|
15277394 |
2004 |
|
Atherothrombosis
|
0.040 |
Biomarker
|
disease |
BEFREE |
GPVI (Glycoprotein VI) is the essential platelet collagen receptor in atherothrombosis.
|
28751543 |
2017 |
|
Atherothrombosis
|
0.040 |
Biomarker
|
disease |
BEFREE |
Platelet glycoprotein VI (GPVI) acts as a decisive collagen receptor in atherothrombosis.
|
29378359 |
2018 |
|
Atherothrombosis
|
0.040 |
Biomarker
|
disease |
BEFREE |
In conclusion, low blood concentrations of ibrutinib and the novel Btk inhibitors suffice for GPVI selective platelet inhibition relevant for atherothrombosis but do not impair primary haemostasis.
|
30685871 |
2019 |
|
Atherothrombosis
|
0.040 |
Biomarker
|
disease |
BEFREE |
Interaction of von Willebrand factor (VWF) with platelet glycoprotein Ib (GPIb) and interaction of collagen with GPVI are essential for thrombus formation on ruptured or eroded atherosclerotic plaques (atherothrombosis).
|
29559479 |
2018 |
|
Autoimmune thrombocytopenia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Significant Hypo-Responsiveness to GPVI and CLEC-2 Agonists in Pre-Term and Full-Term Neonatal Platelets and following Immune Thrombocytopenia.
|
29695020 |
2018 |
|
Basophilic leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
To identify the thiol involved in disulfide bond formation, wild-type or mutant GPVI, where two available sulfhydryls (Cys-274 and Cys-338) were individually mutated to serine, was expressed in rat basophilic leukemia cells.
|
17690106 |
2007 |
|
Blood Coagulation Disorders
|
0.060 |
Biomarker
|
group |
BEFREE |
Human patients with defects associated with the platelet collagen receptor, glycoprotein (GP)VI, are rare and usually described as having a mild bleeding disorder.
|
17910626 |
2007 |
|
Blood Coagulation Disorders
|
0.060 |
GeneticVariation
|
group |
BEFREE |
A compound heterozygous mutation in glycoprotein VI in a patient with a bleeding disorder.
|
19552682 |
2009 |
|
Blood Coagulation Disorders
|
0.060 |
Biomarker
|
group |
BEFREE |
Collagen III has two major hemostasis domains, with binding motifs for von Willebrand factor, α2β1 integrin, platelet binding octapeptide and glycoprotein VI, consistent with the bleeding tendency observed with COL3A1 disease-causing sequence variants.
|
28704418 |
2017 |
|
Blood Coagulation Disorders
|
0.060 |
Biomarker
|
group |
BEFREE |
Complete or partial deficiency of GPVI in humans is a rare condition presenting as a mild bleeding disorder.
|
23815599 |
2013 |
|
Blood Coagulation Disorders
|
0.060 |
Biomarker
|
group |
BEFREE |
Individuals with low VWF due to blood group 0 and low platelet collagen receptor density often exhibit a bleeding tendency, e.g. bleedings from mucosal membranes or menorrhagia in females.
|
20680227 |
2010 |
|
Blood Coagulation Disorders
|
0.060 |
Biomarker
|
group |
BEFREE |
Although Btk plays an important role in platelet signalling, increased bleeding tendency in patients on ibrutinib is more complex than Btk inhibition alone and is because of several antiplatelet mechanisms, namely inhibition of Btk and Tec kinases, which play a key role in platelet activation downstream of the collagen GPVI and Glycoprotein Ib.
|
29995658 |
2018 |
|
Blood Protein Measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Co-regulatory networks of human serum proteins link genetics to disease.
|
30072576 |
2018 |
|
Cardiac Arrhythmia
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
The expression level of this platelet collagen receptor may play a central role in the rapidly evolving coronary artery lesions that lead to malignant arrhythmia and sudden cardiac death.
|
10822074 |
2000 |
|
Cardiovascular Diseases
|
0.030 |
Biomarker
|
group |
BEFREE |
This review summarises the potential of GPVI for diagnostic and therapeutic options based on novel non-invasive molecular imaging modalities to ameliorate care of patients with cardiovascular diseases.
|
24553806 |
2014 |